-
Healthcare at a crossroads as America re-evaluates its approach
As healthcare undergoes one of its most volatile chapters in recent memory, some major developments signal a deeper reckoning with how America manages its medicines,…
-
GRIP Extra: CFTC nominee Quintenz quizzed by senators, FDA to use AI for drug approvals
Our in-brief roundup of notable stories from last week.
-
FDA launches AI tool for its medical researchers and investigators
The FDA has released Elsa, an AI tool designed to optimize the performance of FDA employees such as researchers and investigators.
-
Drug prices in executive and legislative cross-hairs
The rising cost of prescription drugs is a concern for patients, healthcare providers and policymakers, but crafting a solution without undermining industry confidence is tricky.
-
FDA announces AI rollout timeline and scientific review pilot completion
The FDA said its timing to scale use of AI inside its FDA centers follows the completion of a GenAI pilot for scientific review.
-
FDA signals unannounced inspections at foreign manufacturing facilities
The FDA noted how foreign companies have been given advanced notice before facility inspections, while American manufacturers have not.
-
Pharma conference digs into Gilead case, executive orders, CMS audits
At the annual pharmaceutical compliance event, speakers discussed the Gilead False Claims Case and Trump administration initiatives.
-
Pharma watch: Delayed vaccine decisions, insulin price lawsuit, drug cap win
Updates on US pharmaceutical policy, compliance, and regulation.